Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Deffered Revenue (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $2.8 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 83.11% to $2.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Sep 2025, down 83.11% year-over-year, with the annual reading at $11.7 million for FY2024, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $2.8 million in Q3 2025 for Protagonist Therapeutics, down from $5.4 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $28.9 million in Q1 2024 to a low of $2.8 million in Q3 2025.